Cederbaum Stephen D, Koo-McCoy Samantha, Tein Ingrid, Hsu Betty Y L, Ganguly Arupa, Vilain Eric, Dipple Katrina, Cvitanovic-Sojat Ljerka, Stanley Charles
Department of Psychiatry, UCLA, 760 Westwood Plaza, Los Angeles, CA 90024-1759, USA.
Mol Genet Metab. 2002 Nov;77(3):195-201. doi: 10.1016/s1096-7192(02)00169-5.
Three older patients were diagnosed with systemic carnitine deficiency in childhood nearly a generation ago and have together been treated for more than 50 patient years. Treatment improved tissue carnitine stores (proven in two) and eliminated most of the signs and symptoms of carnitine deficiency. All three have continued to respond to carnitine therapy and remain well except for the irreversible sequelae of the pretreatment illnesses. We demonstrate here that transformed lymphocytes from the first documented case of plasma membrane carnitine transporter deficiency fail to take up carnitine from the medium. The analysis of the cDNA of this patient and his parents revealed a homozygous frameshift mutation, 1027delT in exon 4. The resulting polypeptide terminates after amino acid 295. His parents are heterozygous for this mutation. The deletion resulted in predominately abnormal mRNA splicing with either a 13 or 19bp insertion between the junction of exons 3 and 4. The 13/19bp insertions were found in both parents, predominantly in cis with the deletion, and rarely seen with normal alleles from either parents or controls.
